Ocumension Therapeutics

Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. Additionally, EyePoint is advancing its pipeline with innovative therapies such as EYP-1901, targeting wet age-related macular degeneration and diabetic retinopathy, and YUTIQ50 for uveitis. The company employs its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems that provide controlled drug delivery over extended periods. EyePoint has established strategic collaborations with various organizations to enhance its product offerings and has a commercial alliance for the joint promotion of DEXYCU. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was formerly known as pSivida Corp. and rebranded in March 2018.